Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Amantadine (Primary)
- Indications Movement disorders; Multiple sclerosis
- Focus Adverse reactions; Proof of concept
- Sponsors Adamas Pharmaceuticals
- 17 Feb 2017 Results published in the Adamas Pharmaceuticals Media Release.
- 17 Feb 2017 According to Adamas Pharmaceuticals media release, results will be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2017.
- 07 Dec 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History